BMC gastroenterology · 2025
BIGH3 as a potential biomarker for fibrosis in metabolic dysfunction-associated steatotic liver disease: insights from mouse and human studies.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhuang Zhenjie, Zhuge Fen, Liu Yinlan, Song Yu, Luo Yan, Liu Jing, Yang Wenjun, Kong Jianing, Zhang Huiqin, Yang Jin, Shi Junping
Аннотация
BACKGROUND: Liver fibrosis is the strongest predictor of long-term clinical outcomes in patients with metabolic dysfunction-associated steatotic liver disease MASLD. Non-invasive methods for identifying these patients are urgently needed. We aimed to investigate the link between the transforming growth factor-β induced protein Ig-H3 (BIGH3) and fibrosis in both diet-induced mouse model and patients with MASLD, and explore its potential use as a biomarker for MASLD related fibrosis.
METHODS: Hepatic gene expression and serum BIGH3 levels were studied in two diet -induced MASLD models. Forty patients with biopsy-proven MASLD were recruited. Serum BIGH3 levels were measured by enzyme-linked immunosorbent assays. The difference between groups with or without fibrosis was analyzed using the Mann-Whitney U test. BIGH3 levels across different fibrosis stages were analyzed using Spearman correlation, Kruskal-Wallis test, and Dunn's post-hoc test. The receiver operating characteristic (ROC) curve was used to explore its value in the diagnosis of MASLD related fibrosis.
RESULTS: Bigh3 was identified as a fibrosis-related gene in the liver. Serum BIGH3 levels were significantly higher in the mouse model of fibrosis than in controls (P < 0.01). Additionally, serum BIGH3 levels were significantly elevated in MASLD patients with fibrosis compared to those without fibrosis (P < 0.01), and showed a stepwise increase corresponding to the degree of fibrosis (ρ = 0.55, P < 0.01). The areas under the receiver operating characteristic curve to discriminate significant fibrosis were 0.790 (P < 0.01).
CONCLUSION: BIGH3 is a potential non-invasive biomarker of MASLD related fibrosis. It may be beneficial for diagnosing significant fibrosis in MASLD patients.
METHODS: Hepatic gene expression and serum BIGH3 levels were studied in two diet -induced MASLD models. Forty patients with biopsy-proven MASLD were recruited. Serum BIGH3 levels were measured by enzyme-linked immunosorbent assays. The difference between groups with or without fibrosis was analyzed using the Mann-Whitney U test. BIGH3 levels across different fibrosis stages were analyzed using Spearman correlation, Kruskal-Wallis test, and Dunn's post-hoc test. The receiver operating characteristic (ROC) curve was used to explore its value in the diagnosis of MASLD related fibrosis.
RESULTS: Bigh3 was identified as a fibrosis-related gene in the liver. Serum BIGH3 levels were significantly higher in the mouse model of fibrosis than in controls (P < 0.01). Additionally, serum BIGH3 levels were significantly elevated in MASLD patients with fibrosis compared to those without fibrosis (P < 0.01), and showed a stepwise increase corresponding to the degree of fibrosis (ρ = 0.55, P < 0.01). The areas under the receiver operating characteristic curve to discriminate significant fibrosis were 0.790 (P < 0.01).
CONCLUSION: BIGH3 is a potential non-invasive biomarker of MASLD related fibrosis. It may be beneficial for diagnosing significant fibrosis in MASLD patients.